Current Reviews in Clinical and Experimental Pharmacology

Scope & Guideline

Transforming Pharmacological Science with Current Reviews

Introduction

Welcome to the Current Reviews in Clinical and Experimental Pharmacology information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Current Reviews in Clinical and Experimental Pharmacology, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2772-4328
PublisherBENTHAM SCIENCE PUBL LTD
Support Open AccessNo
CountryUnited Arab Emirates
TypeJournal
Convergefrom 2021 to 2024
AbbreviationCURR REV CLIN EXP PH / Curr. Rev. Clin. Exper. Pharmacol.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressEXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES

Aims and Scopes

Current Reviews in Clinical and Experimental Pharmacology is dedicated to providing comprehensive reviews and analyses of current research in pharmacology, with a strong emphasis on clinical applications and translational medicine. The journal aims to bridge the gap between laboratory-based research and clinical practice, addressing significant issues in drug development, pharmacotherapy, and the safety and efficacy of medications.
  1. Clinical Pharmacology and Therapeutics:
    The journal focuses on the effects, safety, and efficacy of drugs in clinical settings, providing insights into therapeutic interventions and management of various diseases.
  2. Translational Research:
    It emphasizes the importance of translating laboratory findings into clinical applications, exploring new therapeutic targets, drug mechanisms, and treatment strategies.
  3. Systematic Reviews and Meta-Analyses:
    The journal frequently publishes systematic reviews and meta-analyses to synthesize evidence regarding pharmacological treatments and interventions, aiding in clinical decision-making.
  4. Emerging Therapies and Novel Drug Development:
    Current Reviews highlights innovative drug formulations, repurposing existing medications, and the exploration of alternative therapies such as natural compounds and nutraceuticals.
  5. Preclinical and Experimental Models:
    The journal discusses preclinical studies and experimental models that are crucial for understanding drug mechanisms and testing new therapeutic approaches.
The journal has seen a significant evolution in its thematic focus, with several emerging trends that reflect contemporary challenges and advancements in pharmacology and therapeutics. These trends highlight the journal's responsiveness to the changing landscape of medical research and clinical needs.
  1. Integrative and Multidisciplinary Approaches:
    There is a growing trend towards integrative studies that combine pharmacology with other disciplines, such as genomics, proteomics, and systems biology, to enhance therapeutic efficacy.
  2. Natural Products and Herbal Medicine:
    Recent publications have increasingly highlighted the role of natural products and herbal compounds in pharmacotherapy, reflecting a renewed interest in alternative and complementary medicines.
  3. Patient-Centric Research:
    Emerging themes emphasize the importance of patient perspectives, adherence, and individualized treatment strategies, aligning with the broader movement towards patient-centered care.
  4. Advanced Therapeutic Modalities:
    The journal is increasingly publishing research on advanced therapeutic modalities, such as gene therapy, cell therapy, and nanotechnology, indicating a shift towards innovative treatment options.
  5. Drug Repurposing and Safety Profiles:
    There is a notable increase in studies focusing on drug repurposing strategies and the safety profiles of existing medications, particularly in the context of emerging health crises like the COVID-19 pandemic.

Declining or Waning

Over the years, certain themes within the journal have begun to lose prominence, reflecting shifts in research focus and evolving priorities in pharmacology and clinical practice. This decline may indicate changing trends in drug development, therapeutic approaches, and clinical research methodologies.
  1. Traditional Pharmacotherapy:
    There appears to be a waning interest in traditional pharmacotherapy approaches without innovative angles, as more research is focused on novel therapies and drug repurposing.
  2. Single-Agent Drug Studies:
    Research that solely focuses on the efficacy of single-agent drugs without considering combination therapies or multi-target approaches is becoming less common.
  3. Historical Reviews of Established Drugs:
    While historical reviews of established drugs were once prevalent, there is now a shift towards investigating new compounds and their potential applications.
  4. Pharmacokinetics in Stable Populations:
    Studies focusing on pharmacokinetics in stable populations are declining as the journal shifts towards more dynamic and complex patient populations, including those with comorbidities.
  5. Basic Science without Clinical Relevance:
    Research that emphasizes basic science without a clear pathway to clinical application is becoming less favored in favor of studies with direct clinical implications.

Similar Journals

CLINICAL DRUG INVESTIGATION

Connecting researchers to the forefront of drug discovery.
Publisher: ADIS INT LTDISSN: 1173-2563Frequency: 12 issues/year

CLINICAL DRUG INVESTIGATION is a prestigious journal dedicated to the fields of Medicine and Pharmacology, published by ADIS INT LTD in the United Kingdom. With an ISSN of 1173-2563 and an E-ISSN of 1179-1918, this journal has been a crucial contributor to the scientific community since its inception in 1995. Recognized for its significant impact, it holds a commendable Q2 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories, placing it firmly in the 70th percentile within its field. Researchers, professionals, and students alike benefit from its commitment to publishing innovative studies and comprehensive reviews that advance understanding and application of clinical drugs. Although it does not currently offer open access options, its rigorous peer-review process ensures the integrity and quality of published articles. The journal's scope encompasses a wide range of topics related to drug investigation, making it an essential resource for anyone involved in medical research and pharmacological practice.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Shaping the Future of Therapeutics Through Rigorous Inquiry
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0022-3565Frequency: 12 issues/year

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.

Asian Journal of Pharmaceutics

Illuminating the future of drug development and regulatory affairs.
Publisher: ASIAN JOURNAL PHARMACEUTICSISSN: 0973-8398Frequency: 4 issues/year

Asian Journal of Pharmaceutics, with ISSN 0973-8398 and E-ISSN 1998-409X, is a prominent publication in the field of pharmacology, toxicology, and pharmaceutics, published by the ASIAN JOURNAL PHARMACEUTICS. Since its inception in 2009, the journal has been committed to advancing the understanding of pharmaceutical sciences in Asia and beyond, encompassing innovative research, reviews, and perspectives from both established and emerging scholars. Despite its coverage discontinuation in Scopus, it continues to serve as a vital resource for researchers, professionals, and students aiming to explore the dynamic developments in drug formulation, delivery systems, and regulatory affairs. The journal's ranking in the 18th percentile within its category underscores its niche focus and relevance, making it an essential conduit for disseminating knowledge in the pharmaceutical domain. Open access options may enhance its reach and impact, allowing significant findings to be freely accessible to a global audience, thus fostering collaboration and knowledge exchange across borders.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Navigating the Complexities of Drug Action and Toxicity
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

Journal of Pharmacy & Pharmacognosy Research

Bridging Science and Practice in Pharmacy
Publisher: JOURNAL PHARMACY & PHARMACOGNOSY RESEARCH-JPPRESISSN: 0719-4250Frequency: 6 issues/year

Journal of Pharmacy & Pharmacognosy Research, published by JOURNAL PHARMACY & PHARMACOGNOSY RESEARCH-JPPRES, is a prominent open-access journal established in 2013, headquartered in Antofagasta, Chile. With a focus on the fields of Complementary and Alternative Medicine, Drug Discovery, Pharmaceutical Science, Pharmacology, and Pharmacy, this journal is recognized for its commitment to advancing research and disseminating knowledge within these important areas. With a current impact factor that reflects its academic rigor and relevance, the journal has achieved substantial recognition, evident by its Q2 and Q3 quartile rankings in multiple categories, indicating its growing influence on the scientific community. The Scopus rankings further highlight its standing in pharmacy and pharmacological disciplines, providing a valuable platform for researchers, professionals, and students to share their findings and insights. With its open access model, the journal ensures that high-quality research is available to a global audience, paving the way for collaborative advancements in pharmaceutical sciences.

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Unveiling Cutting-Edge Developments in Drug and Body Dynamics
Publisher: WILEYISSN: 0305-1870Frequency: 12 issues/year

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, published by WILEY, is a premier journal that serves as a vital resource for researchers, professionals, and students in the fields of pharmacology and physiology. With ISSN 0305-1870 and E-ISSN 1440-1681, this journal has established itself as a significant contributor to scientific dialogue since its inception in 1974. Currently spanning until 2024, it consistently publishes cutting-edge research addressing both experimental and clinical advancements in pharmacology and physiology. Recognized for its quality, it holds a Q2 ranking in the 2023 Pharmacology category and notable Q3 rankings in both Physiology and Medical Physiology. The journal's coverage of topical issues not only ensures a robust platform for innovative findings but also fosters collaborations across disciplines. Although not an Open Access journal, its curated content is invaluable for advancing knowledge, as evidenced by its solid Scopus rankings, which place it within the top percentiles of its field. Engaging with this journal means staying at the forefront of research that shapes clinical practices and experimental methodologies.

JOURNAL OF CLINICAL PHARMACOLOGY

Innovating Insights in Clinical Pharmacology
Publisher: WILEYISSN: 0091-2700Frequency: 12 issues/year

Welcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.

CURRENT OPINION IN PHARMACOLOGY

Exploring the Frontiers of Drug Discovery
Publisher: ELSEVIER SCI LTDISSN: 1471-4892Frequency: 6 issues/year

Current Opinion in Pharmacology, an esteemed journal published by Elsevier Science Ltd, encompasses the vital field of pharmacology and drug discovery. With a solid impact factor and recognized as a Q1 journal in both Drug Discovery and Pharmacology categories for 2023, it serves as a premier platform for researchers and professionals to share innovative insights, discuss emerging trends, and explore the complexities of drug development and therapeutic applications. Established in 2001 and running through 2024, this journal provides a critical overview of advances in the field, aiming to inform and inspire the next generation of pharmacological research. Despite lacking Open Access options, it maintains a high standard of scholarly excellence, ensuring that the content remains impactful and relevant to its readers. The journal is based in the Netherlands, representing a key contributor to the academic landscape in pharmacology.

Acta Pharmaceutica Sinica B

Championing Excellence in Pharmaceutical Research
Publisher: INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCESISSN: 2211-3835Frequency: 6 issues/year

Acta Pharmaceutica Sinica B is a prestigious open access journal that has been setting the standard in the field of pharmacology, toxicology, and pharmaceutics since its establishment in 2011. Published by the Institute of Materia Medica, Chinese Academy of Medical Sciences, the journal serves as a vital platform for researchers, professionals, and students seeking to disseminate innovative findings in drug development, pharmaceutical sciences, and therapeutic applications. With an impressive impact factor reflecting its high academic quality, Acta Pharmaceutica Sinica B has achieved Q1 status in the category of Pharmacology, Toxicology and Pharmaceutics as of 2023, ranking #1 out of 80 journals in General Pharmacology. This journal not only focuses on the latest advancements in drug research and formulation but also emphasizes interdisciplinary approaches, fostering collaborations that span various scientific domains. The accessible nature of the journal, combined with its rigorous peer-review process, ensures that crucial insights and breakthroughs reach a global audience swiftly and effectively. For those looking to stay at the forefront of pharmaceutical research, Acta Pharmaceutica Sinica B is an indispensable resource.

INDIAN JOURNAL OF PHARMACOLOGY

Exploring the frontiers of pharmacology since 1978.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0253-7613Frequency: 6 issues/year

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.